ARISE Clinical Trial half-time on the road

Patient inclusion to the ARISE trial is proceeding nicely. Figure 1 is showing the numbers of patients operated within the trial already as well as the number of scheduled operations. Therefore the ARISE consortium is confident... [more]

Presentation at the STS/AATS Tech-Con on Saturday 21, 2017 in Houston, Texas about the ARISE study

The ARISE study will be presented at the Society of Thoracic Surgeons 53rd annual meeting during the STS/AATS Tech-Con on Saturday 21st in Houston, Texas (10:15-12:00 pm Adult Cardiac Track/Endovascular. Moderators: Michael... [more]

ESPOIR project closing meeting held in Zurich in December 2016

Long-term follow up initiated - the European post-authorisation study on regenerative pulmonary heart valve replacement enrolled 120 patients [more]

Welcome to ARISE

65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. None of the currently available prostheses for AVR is tailored toward the individual patient or allows for individual regeneration. The ARISE project will bridge this therapeutic gap in a clinical study to determine the feasibility, safety and efficacy of regenerative heart valves for aortic valve replacement.